| Website | hydrabiosciences.com |
| Category | BioTech |
| Phone | 617-494-5230 |
| Employees | |
| Description | Biopharmaceutical company |
| TOTAL | $22M |
| VENTURE FUNDING TOTAL | $22M |
| Series D, 1/09 MedImmune Ventures | $22M |
Hydra Biosciences, a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra’s proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.
Hydra’s ion channel drug discovery program is currently focused on channels implicated in pain, inflammation and cardiovascular disease. Hydra’s intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium or potassium voltage-gated channels Hydra’s novel ion channels provide the potential to develop selective and safer ion channel drugs.
Hydra has raised significant financing from blue chip investors since its inception. This prominent group of investors include: Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
